broprodifacoum;3-[3-(4'-bromo[1,1'-biphenyl]-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-1-benzopyran-2-one

3-[3-(4'-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxycoumarin

C₃₀H₂₃BrO₄

Form Yellowish powder.

Melting point 200-210℃.

Density 1.5164.

Solubility In water 19 mg/l (20℃). In dimethylformamide 730, ethyl acetate 25, ethanol 8.2 (all in g/l, 20℃). Soluble in acetone; slightly soluble in chloroform; practically insoluble in diethyl ether and hexane.

Oral Acute oral LD50 for rats 1.125, mice 1.75, rabbits 1.00, dogs >10.0, cats >25.0 mg/kg.

Skin and eye Acute percutaneous LD50 for rabbits 1.71 mg/kg.

Inhalation LC50 for male and female rats 0.43 mg/l.

Control of rats and mice (including those resistant to warfarin) in areas containing stored products, household use, industrial buildings, and other situations.

Description: White or off-white powder,free from visible extraneous matter;

Active Ingredient Content(w/w): ≥98%;

Water (w/w): ≤0.5%; Loss on Drying(w/w): ≤1.0%;

pH Value: 5.0~9.0;

Bromadiolone A and B scale α(A/B): ≤0.3